Rasburicase
Uric Acid-specific Enzyme — VARIOUS
Also known as: elitek, fasturtec
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Rasburicase is a drug in the Uric Acid-specific Enzyme class catalogued in DrugCentral. It was first approved by the EMA in 2001. Recorded indications include Hyperuricemia.
- Drug class: Uric Acid-specific Enzyme.
- Indications: Hyperuricemia.
- ATC code: V03AF07 (Detoxifying agents for antineoplastic treatment).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hyperuricemia
Mechanism & targets
| Established pharmacologic class | Uric Acid-specific Enzyme |
|---|
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2002-07-12 | FDA | — | SANOFI SYNTHELABO | |
| 2001-02-23 | EMA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V03AF07 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: G6PD · Actionable PGx
- FDA label: CYB5R1, CYB5R2, CYB5R3, CYB5R4 · Informative PGx
- FDA label: G6PD · Testing Required
- HCSC label: G6PD · Testing Required
- PMDA label: G6PD · Actionable PGx
- Swissmedic label: G6PD · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Tumour lysis syndrome | 1355.6 |
| Methaemoglobinaemia | 463.9 |
| Febrile neutropenia | 339.5 |
| Cytokine release syndrome | 332.3 |
| Lymphoid tissue hypoplasia | 295.6 |
| Thymus hypoplasia | 287.8 |
| Disseminated aspergillosis | 244.6 |
| Neutropenia | 203.1 |
| Lymphopenia | 190.6 |
| Haemolytic anaemia | 187.5 |
| Cytomegalovirus viraemia | 130.7 |
| Bacterial infection | 115.5 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 134774-45-1 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Rasburicase used for?
DrugCentral lists the following indications for Rasburicase: Hyperuricemia.
When was Rasburicase first approved?
Rasburicase was first approved by the EMA in 2001.
What drug class does Rasburicase belong to?
Rasburicase is in the Uric Acid-specific Enzyme class.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4994 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201594 — compound record and bioactivity
- DrugBank DB00049 — drug record
- FDA UNII 08GY9K1EUO — substance identity
- DailyMed: FDA labels for Rasburicase — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.